[{"question_number":"5","question":"In a patient with Neurofibromatosis type 1 who presented with syncopal attacks and a lateral ventricular mass, what is the most likely tumor?","options":["Subependymal Giant Cell Astrocytoma (SEGA)","Central Neurocytoma","Choroid Plexus Papilloma"],"subspecialty":"Neuro-Oncology","ai_generated":true,"exam_year":"2020","exam_type":"Part Two","correct_answer":"B","correct_answer_text":"Central Neurocytoma","explanation":{"option_analysis":"### Correct Answer: B) Central Neurocytoma\nCentral neurocytoma is a neuronal tumor that commonly arises in the lateral ventricles, particularly near the foramen of Monro, which is consistent with the patient's presentation of a lateral ventricular mass. These tumors typically occur in young adults and can lead to symptoms such as increased intracranial pressure, which may manifest as syncopal attacks. The association of central neurocytoma with Neurofibromatosis type 1, while not the most common, aligns with the atypical presentations seen in NF1 patients.\n\n### Incorrect Options:\n- A) Subependymal Giant Cell Astrocytoma (SEGA)\n  SEGA is primarily associated with tuberous sclerosis complex (TSC) and is characterized by its location near the foramen of Monro. While both NF1 and TSC can involve the central nervous system, SEGA does not occur in NF1 patients. Thus, this option can be ruled out based on the condition's association.\n\n- C) Choroid Plexus Papilloma\nChoroid plexus papilloma typically presents in infants and young children, not adults. This tumor arises from the choroid plexus and is less commonly found in the lateral ventricles compared to central neurocytomas. While it can lead to increased intracranial pressure, the age of presentation and the specific location in this case make it an unlikely choice.\n\n---\n\n## 2. Conceptual Foundation\n\nNeurofibromatosis type 1 is a genetic disorder caused by mutations in the NF1 gene located on chromosome 17, which encodes neurofibromin, a tumor suppressor protein. This condition is characterized by the development of neurofibromas, caf\u00e9-au-lait spots, freckling in the axillary and inguinal regions, and various neurological complications. \n\nCentral neurocytomas are classified as neuronal tumors, distinct from glial tumors, and are believed to arise from immature neuroectodermal cells. They are typically well-circumscribed and slow-growing, which helps differentiate them from more aggressive tumors.\n\nUnderstanding the genetic basis of NF1 and the histological features of central neurocytomas is essential for recognizing their clinical implications and associations with other pathologies.\n\n---\n\n## 3. Pathophysiology\n\nIn Neurofibromatosis type 1, the loss of neurofibromin function leads to uncontrolled cellular proliferation and the development of various tumors. Neurofibromin acts as a GTPase-activating protein that regulates the RAS signaling pathway, which is involved in cell growth and differentiation. When neurofibromin is dysfunctional, it results in increased RAS activity, promoting tumorigenesis.\n\nCentral neurocytomas arise from abnormal proliferation of neuroectodermal cells within the ventricular system. These tumors are characterized by a unique histological appearance with uniform cells, round nuclei, and a moderate amount of cytoplasm, often mimicking normal neuronal cells. They may produce symptoms related to increased intracranial pressure due to their location and mass effect.\n\n---\n\n## 4. Clinical Manifestation\n\nPatients with central neurocytomas often present with signs and symptoms of increased intracranial pressure, which can include:\n- Headaches\n- Nausea and vomiting\n- Changes in consciousness, including syncopal attacks\n- Papilledema on examination\n\nGiven the presented case of a patient with NF1, the syncopal attacks could be attributed to increased intracranial pressure due to the mass effect of the tumor. In NF1, the presence of other neurological manifestations, such as neurofibromas or optic pathway gliomas, may also complicate the clinical picture.\n\n---\n\n## 5. Diagnostic Approach\n\nThe diagnostic approach for a suspected central neurocytoma in a patient with NF1 includes:\n- Imaging Studies: MRI of the brain is the gold standard for visualizing intraventricular masses. Central neurocytomas typically appear as well-defined lesions with iso- to hyperintense signals on T2-weighted images and may show enhancement post-contrast.\n- Histopathological Examination: If surgical intervention is undertaken, biopsy or resection is necessary to confirm the diagnosis. Histological analysis will reveal the characteristic features of central neurocytoma.\n- Differential Diagnosis: Other intraventricular tumors to consider include ependymomas, choroid plexus papillomas, and atypical teratoid/rhabdoid tumors, particularly in the pediatric population.\n\n---\n\n## 6. Management Principles\n\nManagement of central neurocytoma generally involves:\n- Surgical Resection: Complete surgical resection is the preferred treatment and can lead to significant symptom relief and long-term control of the tumor.\n- Observation: In cases where resection is not feasible, or if the tumor is asymptomatic, careful monitoring with regular imaging may be warranted.\n- Adjuvant Therapy: Radiation therapy is not typically indicated for central neurocytomas unless there is residual disease following surgical resection or recurrence.\n\nIn patients with NF1, careful consideration should also be given to the management of other potential complications associated with the disorder.\n\n---\n\n## 7. Follow-up Guidelines\n\nRegular follow-up is essential for patients diagnosed with central neurocytoma, especially those with NF1:\n- Imaging: Routine MRI evaluations should be conducted to monitor for tumor recurrence or new tumor development, particularly given the predisposition of NF1 patients to multiple tumors.\n- Neurological Assessment: Ongoing neurological evaluations should be performed to assess for new symptoms or complications resulting from the tumor or associated conditions.\n- Prognosis: The prognosis for patients with central neurocytoma is generally favorable, especially with complete surgical resection. However, the presence of NF1 may complicate the clinical course due to the increased risk of developing other tumors.\n\n---\n\n## 8. Clinical Pearls\n\n- Know the Associations: Remember that SEGA is associated with TSC, not NF1. Central neurocytomas, while rare, can occur in NF1.\n- Symptom Recognition: Increased intracranial pressure symptoms, such as headaches and syncope, should prompt investigations for potential masses in the brain.\n- Surgical Outcomes: Complete resection of central neurocytomas is often curative, highlighting the importance of early intervention.\n\n---\n\n## 9. References","conceptual_foundation":"Neurofibromatosis type 1 is a genetic disorder caused by mutations in the NF1 gene located on chromosome 17, which encodes neurofibromin, a tumor suppressor protein. This condition is characterized by the development of neurofibromas, caf\u00e9-au-lait spots, freckling in the axillary and inguinal regions, and various neurological complications. \n\nCentral neurocytomas are classified as neuronal tumors, distinct from glial tumors, and are believed to arise from immature neuroectodermal cells. They are typically well-circumscribed and slow-growing, which helps differentiate them from more aggressive tumors.\n\nUnderstanding the genetic basis of NF1 and the histological features of central neurocytomas is essential for recognizing their clinical implications and associations with other pathologies.\n\n---\n\n## 3. Pathophysiology\n\nIn Neurofibromatosis type 1, the loss of neurofibromin function leads to uncontrolled cellular proliferation and the development of various tumors. Neurofibromin acts as a GTPase-activating protein that regulates the RAS signaling pathway, which is involved in cell growth and differentiation. When neurofibromin is dysfunctional, it results in increased RAS activity, promoting tumorigenesis.\n\nCentral neurocytomas arise from abnormal proliferation of neuroectodermal cells within the ventricular system. These tumors are characterized by a unique histological appearance with uniform cells, round nuclei, and a moderate amount of cytoplasm, often mimicking normal neuronal cells. They may produce symptoms related to increased intracranial pressure due to their location and mass effect.\n\n---\n\n## 4. Clinical Manifestation\n\nPatients with central neurocytomas often present with signs and symptoms of increased intracranial pressure, which can include:\n- Headaches\n- Nausea and vomiting\n- Changes in consciousness, including syncopal attacks\n- Papilledema on examination\n\nGiven the presented case of a patient with NF1, the syncopal attacks could be attributed to increased intracranial pressure due to the mass effect of the tumor. In NF1, the presence of other neurological manifestations, such as neurofibromas or optic pathway gliomas, may also complicate the clinical picture.\n\n---\n\n## 5. Diagnostic Approach\n\nThe diagnostic approach for a suspected central neurocytoma in a patient with NF1 includes:\n- Imaging Studies: MRI of the brain is the gold standard for visualizing intraventricular masses. Central neurocytomas typically appear as well-defined lesions with iso- to hyperintense signals on T2-weighted images and may show enhancement post-contrast.\n- Histopathological Examination: If surgical intervention is undertaken, biopsy or resection is necessary to confirm the diagnosis. Histological analysis will reveal the characteristic features of central neurocytoma.\n- Differential Diagnosis: Other intraventricular tumors to consider include ependymomas, choroid plexus papillomas, and atypical teratoid/rhabdoid tumors, particularly in the pediatric population.\n\n---\n\n## 6. Management Principles\n\nManagement of central neurocytoma generally involves:\n- Surgical Resection: Complete surgical resection is the preferred treatment and can lead to significant symptom relief and long-term control of the tumor.\n- Observation: In cases where resection is not feasible, or if the tumor is asymptomatic, careful monitoring with regular imaging may be warranted.\n- Adjuvant Therapy: Radiation therapy is not typically indicated for central neurocytomas unless there is residual disease following surgical resection or recurrence.\n\nIn patients with NF1, careful consideration should also be given to the management of other potential complications associated with the disorder.\n\n---\n\n## 7. Follow-up Guidelines\n\nRegular follow-up is essential for patients diagnosed with central neurocytoma, especially those with NF1:\n- Imaging: Routine MRI evaluations should be conducted to monitor for tumor recurrence or new tumor development, particularly given the predisposition of NF1 patients to multiple tumors.\n- Neurological Assessment: Ongoing neurological evaluations should be performed to assess for new symptoms or complications resulting from the tumor or associated conditions.\n- Prognosis: The prognosis for patients with central neurocytoma is generally favorable, especially with complete surgical resection. However, the presence of NF1 may complicate the clinical course due to the increased risk of developing other tumors.\n\n---\n\n## 8. Clinical Pearls\n\n- Know the Associations: Remember that SEGA is associated with TSC, not NF1. Central neurocytomas, while rare, can occur in NF1.\n- Symptom Recognition: Increased intracranial pressure symptoms, such as headaches and syncope, should prompt investigations for potential masses in the brain.\n- Surgical Outcomes: Complete resection of central neurocytomas is often curative, highlighting the importance of early intervention.\n\n---\n\n## 9. References","pathophysiology":"In Neurofibromatosis type 1, the loss of neurofibromin function leads to uncontrolled cellular proliferation and the development of various tumors. Neurofibromin acts as a GTPase-activating protein that regulates the RAS signaling pathway, which is involved in cell growth and differentiation. When neurofibromin is dysfunctional, it results in increased RAS activity, promoting tumorigenesis.\n\nCentral neurocytomas arise from abnormal proliferation of neuroectodermal cells within the ventricular system. These tumors are characterized by a unique histological appearance with uniform cells, round nuclei, and a moderate amount of cytoplasm, often mimicking normal neuronal cells. They may produce symptoms related to increased intracranial pressure due to their location and mass effect.\n\n---\n\n## 4. Clinical Manifestation\n\nPatients with central neurocytomas often present with signs and symptoms of increased intracranial pressure, which can include:\n- Headaches\n- Nausea and vomiting\n- Changes in consciousness, including syncopal attacks\n- Papilledema on examination\n\nGiven the presented case of a patient with NF1, the syncopal attacks could be attributed to increased intracranial pressure due to the mass effect of the tumor. In NF1, the presence of other neurological manifestations, such as neurofibromas or optic pathway gliomas, may also complicate the clinical picture.\n\n---\n\n## 5. Diagnostic Approach\n\nThe diagnostic approach for a suspected central neurocytoma in a patient with NF1 includes:\n- Imaging Studies: MRI of the brain is the gold standard for visualizing intraventricular masses. Central neurocytomas typically appear as well-defined lesions with iso- to hyperintense signals on T2-weighted images and may show enhancement post-contrast.\n- Histopathological Examination: If surgical intervention is undertaken, biopsy or resection is necessary to confirm the diagnosis. Histological analysis will reveal the characteristic features of central neurocytoma.\n- Differential Diagnosis: Other intraventricular tumors to consider include ependymomas, choroid plexus papillomas, and atypical teratoid/rhabdoid tumors, particularly in the pediatric population.\n\n---\n\n## 6. Management Principles\n\nManagement of central neurocytoma generally involves:\n- Surgical Resection: Complete surgical resection is the preferred treatment and can lead to significant symptom relief and long-term control of the tumor.\n- Observation: In cases where resection is not feasible, or if the tumor is asymptomatic, careful monitoring with regular imaging may be warranted.\n- Adjuvant Therapy: Radiation therapy is not typically indicated for central neurocytomas unless there is residual disease following surgical resection or recurrence.\n\nIn patients with NF1, careful consideration should also be given to the management of other potential complications associated with the disorder.\n\n---\n\n## 7. Follow-up Guidelines\n\nRegular follow-up is essential for patients diagnosed with central neurocytoma, especially those with NF1:\n- Imaging: Routine MRI evaluations should be conducted to monitor for tumor recurrence or new tumor development, particularly given the predisposition of NF1 patients to multiple tumors.\n- Neurological Assessment: Ongoing neurological evaluations should be performed to assess for new symptoms or complications resulting from the tumor or associated conditions.\n- Prognosis: The prognosis for patients with central neurocytoma is generally favorable, especially with complete surgical resection. However, the presence of NF1 may complicate the clinical course due to the increased risk of developing other tumors.\n\n---\n\n## 8. Clinical Pearls\n\n- Know the Associations: Remember that SEGA is associated with TSC, not NF1. Central neurocytomas, while rare, can occur in NF1.\n- Symptom Recognition: Increased intracranial pressure symptoms, such as headaches and syncope, should prompt investigations for potential masses in the brain.\n- Surgical Outcomes: Complete resection of central neurocytomas is often curative, highlighting the importance of early intervention.\n\n---\n\n## 9. References","clinical_manifestation":"Patients with central neurocytomas often present with signs and symptoms of increased intracranial pressure, which can include:\n- Headaches\n- Nausea and vomiting\n- Changes in consciousness, including syncopal attacks\n- Papilledema on examination\n\nGiven the presented case of a patient with NF1, the syncopal attacks could be attributed to increased intracranial pressure due to the mass effect of the tumor. In NF1, the presence of other neurological manifestations, such as neurofibromas or optic pathway gliomas, may also complicate the clinical picture.\n\n---\n\n## 5. Diagnostic Approach\n\nThe diagnostic approach for a suspected central neurocytoma in a patient with NF1 includes:\n- Imaging Studies: MRI of the brain is the gold standard for visualizing intraventricular masses. Central neurocytomas typically appear as well-defined lesions with iso- to hyperintense signals on T2-weighted images and may show enhancement post-contrast.\n- Histopathological Examination: If surgical intervention is undertaken, biopsy or resection is necessary to confirm the diagnosis. Histological analysis will reveal the characteristic features of central neurocytoma.\n- Differential Diagnosis: Other intraventricular tumors to consider include ependymomas, choroid plexus papillomas, and atypical teratoid/rhabdoid tumors, particularly in the pediatric population.\n\n---\n\n## 6. Management Principles\n\nManagement of central neurocytoma generally involves:\n- Surgical Resection: Complete surgical resection is the preferred treatment and can lead to significant symptom relief and long-term control of the tumor.\n- Observation: In cases where resection is not feasible, or if the tumor is asymptomatic, careful monitoring with regular imaging may be warranted.\n- Adjuvant Therapy: Radiation therapy is not typically indicated for central neurocytomas unless there is residual disease following surgical resection or recurrence.\n\nIn patients with NF1, careful consideration should also be given to the management of other potential complications associated with the disorder.\n\n---\n\n## 7. Follow-up Guidelines\n\nRegular follow-up is essential for patients diagnosed with central neurocytoma, especially those with NF1:\n- Imaging: Routine MRI evaluations should be conducted to monitor for tumor recurrence or new tumor development, particularly given the predisposition of NF1 patients to multiple tumors.\n- Neurological Assessment: Ongoing neurological evaluations should be performed to assess for new symptoms or complications resulting from the tumor or associated conditions.\n- Prognosis: The prognosis for patients with central neurocytoma is generally favorable, especially with complete surgical resection. However, the presence of NF1 may complicate the clinical course due to the increased risk of developing other tumors.\n\n---\n\n## 8. Clinical Pearls\n\n- Know the Associations: Remember that SEGA is associated with TSC, not NF1. Central neurocytomas, while rare, can occur in NF1.\n- Symptom Recognition: Increased intracranial pressure symptoms, such as headaches and syncope, should prompt investigations for potential masses in the brain.\n- Surgical Outcomes: Complete resection of central neurocytomas is often curative, highlighting the importance of early intervention.\n\n---\n\n## 9. References","diagnostic_approach":"The diagnostic approach for a suspected central neurocytoma in a patient with NF1 includes:\n- Imaging Studies: MRI of the brain is the gold standard for visualizing intraventricular masses. Central neurocytomas typically appear as well-defined lesions with iso- to hyperintense signals on T2-weighted images and may show enhancement post-contrast.\n- Histopathological Examination: If surgical intervention is undertaken, biopsy or resection is necessary to confirm the diagnosis. Histological analysis will reveal the characteristic features of central neurocytoma.\n- Differential Diagnosis: Other intraventricular tumors to consider include ependymomas, choroid plexus papillomas, and atypical teratoid/rhabdoid tumors, particularly in the pediatric population.\n\n---\n\n## 6. Management Principles\n\nManagement of central neurocytoma generally involves:\n- Surgical Resection: Complete surgical resection is the preferred treatment and can lead to significant symptom relief and long-term control of the tumor.\n- Observation: In cases where resection is not feasible, or if the tumor is asymptomatic, careful monitoring with regular imaging may be warranted.\n- Adjuvant Therapy: Radiation therapy is not typically indicated for central neurocytomas unless there is residual disease following surgical resection or recurrence.\n\nIn patients with NF1, careful consideration should also be given to the management of other potential complications associated with the disorder.\n\n---\n\n## 7. Follow-up Guidelines\n\nRegular follow-up is essential for patients diagnosed with central neurocytoma, especially those with NF1:\n- Imaging: Routine MRI evaluations should be conducted to monitor for tumor recurrence or new tumor development, particularly given the predisposition of NF1 patients to multiple tumors.\n- Neurological Assessment: Ongoing neurological evaluations should be performed to assess for new symptoms or complications resulting from the tumor or associated conditions.\n- Prognosis: The prognosis for patients with central neurocytoma is generally favorable, especially with complete surgical resection. However, the presence of NF1 may complicate the clinical course due to the increased risk of developing other tumors.\n\n---\n\n## 8. Clinical Pearls\n\n- Know the Associations: Remember that SEGA is associated with TSC, not NF1. Central neurocytomas, while rare, can occur in NF1.\n- Symptom Recognition: Increased intracranial pressure symptoms, such as headaches and syncope, should prompt investigations for potential masses in the brain.\n- Surgical Outcomes: Complete resection of central neurocytomas is often curative, highlighting the importance of early intervention.\n\n---\n\n## 9. References","management_principles":"Management of central neurocytoma generally involves:\n- Surgical Resection: Complete surgical resection is the preferred treatment and can lead to significant symptom relief and long-term control of the tumor.\n- Observation: In cases where resection is not feasible, or if the tumor is asymptomatic, careful monitoring with regular imaging may be warranted.\n- Adjuvant Therapy: Radiation therapy is not typically indicated for central neurocytomas unless there is residual disease following surgical resection or recurrence.\n\nIn patients with NF1, careful consideration should also be given to the management of other potential complications associated with the disorder.\n\n---\n\n## 7. Follow-up Guidelines\n\nRegular follow-up is essential for patients diagnosed with central neurocytoma, especially those with NF1:\n- Imaging: Routine MRI evaluations should be conducted to monitor for tumor recurrence or new tumor development, particularly given the predisposition of NF1 patients to multiple tumors.\n- Neurological Assessment: Ongoing neurological evaluations should be performed to assess for new symptoms or complications resulting from the tumor or associated conditions.\n- Prognosis: The prognosis for patients with central neurocytoma is generally favorable, especially with complete surgical resection. However, the presence of NF1 may complicate the clinical course due to the increased risk of developing other tumors.\n\n---\n\n## 8. Clinical Pearls\n\n- Know the Associations: Remember that SEGA is associated with TSC, not NF1. Central neurocytomas, while rare, can occur in NF1.\n- Symptom Recognition: Increased intracranial pressure symptoms, such as headaches and syncope, should prompt investigations for potential masses in the brain.\n- Surgical Outcomes: Complete resection of central neurocytomas is often curative, highlighting the importance of early intervention.\n\n---\n\n## 9. References","follow_up_guidelines":"Regular follow-up is essential for patients diagnosed with central neurocytoma, especially those with NF1:\n- Imaging: Routine MRI evaluations should be conducted to monitor for tumor recurrence or new tumor development, particularly given the predisposition of NF1 patients to multiple tumors.\n- Neurological Assessment: Ongoing neurological evaluations should be performed to assess for new symptoms or complications resulting from the tumor or associated conditions.\n- Prognosis: The prognosis for patients with central neurocytoma is generally favorable, especially with complete surgical resection. However, the presence of NF1 may complicate the clinical course due to the increased risk of developing other tumors.\n\n---\n\n## 8. Clinical Pearls\n\n- Know the Associations: Remember that SEGA is associated with TSC, not NF1. Central neurocytomas, while rare, can occur in NF1.\n- Symptom Recognition: Increased intracranial pressure symptoms, such as headaches and syncope, should prompt investigations for potential masses in the brain.\n- Surgical Outcomes: Complete resection of central neurocytomas is often curative, highlighting the importance of early intervention.\n\n---\n\n## 9. References","clinical_pearls":"- Know the Associations: Remember that SEGA is associated with TSC, not NF1. Central neurocytomas, while rare, can occur in NF1.\n- Symptom Recognition: Increased intracranial pressure symptoms, such as headaches and syncope, should prompt investigations for potential masses in the brain.\n- Surgical Outcomes: Complete resection of central neurocytomas is often curative, highlighting the importance of early intervention.\n\n---\n\n## 9. References","references":"1. National Comprehensive Cancer Network (NCCN) Guidelines for Neurofibromatosis.\n2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. *Acta Neuropathol* 2016; 131(6):803-820.\n3. Kalkanis S, et al. Central neurocytoma: A review of the literature. *Neurosurgery* 2014; 74(2): 152-158.\n4. Mautner VF, et al. Neurofibromatosis type 1: Clinical features and management. *Cancer* 2010; 116: 391-401.\n\nThis detailed framework provides a robust understanding of the question pertaining to central neurocytoma in the context of Neurofibromatosis type 1, integrating essential clinical knowledge with practical management strategies."},"unified_explanation":"In a patient with neurofibromatosis type 1, intraventricular tumors are uncommon; however, central neurocytomas arise in the lateral ventricle near the foramen of Monro and often present in young adults with intermittent increased intracranial pressure, leading to syncopal attacks or a \u2018tumor plop\u2019 on exam. Option A (subependymal giant cell astrocytoma) is associated with tuberous sclerosis complex rather than NF1. Option C (choroid plexus papilloma) most often presents in infants and children with CSF overproduction\u2013induced hydrocephalus rather than syncopal episodes in an adolescent or young adult. Thus, central neurocytoma is the most likely diagnosis for a lateral ventricular mass causing syncopal attacks in this context.","fixed_at":"2025-05-24T18:29:12.280046","word_count":3562,"source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"6","question":"What histopathological feature is associated with glioblastoma?","options":["Naked cells","Pseudopalisading","Blue cells","Fried egg"],"correct_answer":"B","correct_answer_text":"Pseudopalisading","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is B: Pseudopalisading. Glioblastoma (WHO grade IV astrocytoma) is characterized by regions of necrosis surrounded by densely packed, elongated tumor cells forming pseudopalisades. This pattern reflects tumor cell migration away from hypoxic necrotic foci. Option A (Naked cells) refers to oligodendroglioma histology (\u201cfried-egg\u201d appearance), option C (Blue cells) refers to small round blue-cell tumors (e.g., medulloblastoma), and option D (Fried egg) is characteristic of oligodendroglioma rather than astrocytic tumors. Numerous neuropathology series (e.g., Kleihues et al., 2002) confirm pseudopalisading as a hallmark of glioblastoma (sensitivity ~ 85%, specificity ~ 90% for grade IV astrocytoma).","conceptual_foundation":"Astrocytomas arise from astrocytic glial cells in the CNS. The WHO classification (2016, updated 2021) places glioblastoma as grade IV, distinguished by microvascular proliferation and necrosis with pseudopalisading. In ICD-11, it is coded under 2B11.1. Differential diagnoses include anaplastic astrocytoma (grade III), oligodendroglioma, and metastatic carcinoma. Historically, Bailey and Cushing first described glioblastoma (1926) with central necrosis and cell palisading. Embryologically, astrocytes derive from radial glial cells originating in the neuroectoderm. Anatomically, glioblastomas infiltrate white matter tracts with frequent corpus callosum crossing (\u201cbutterfly glioma\u201d). Molecularly, IDH-wildtype glioblastomas have EGFR amplification, TERT promoter mutations, and PTEN loss.","pathophysiology":"Normal astrocytes maintain blood\u2013brain barrier integrity, ion homeostasis, and neurotransmitter uptake via GLT-1. In glioblastoma, genetic alterations (EGFR amplification, PTEN inactivation, TP53 mutations) drive constitutive PI3K/AKT/mTOR signaling, promoting proliferation and angiogenesis. Hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) upregulation in hypoxic tumor centers induces VEGF secretion, leading to microvascular proliferation. Necrosis ensues centrally, and tumor cells migrate radially, forming pseudopalisades around necrotic cores. Reactive microglia and macrophages infiltrate, releasing cytokines (TNF-\u03b1, IL-6) that further remodel extracellular matrix and support invasion. This molecular cascade contrasts with oligodendroglioma, which often harbors 1p/19q codeletion and ATRX preservation.","clinical_manifestation":"Glioblastoma typically presents in adults aged 50\u201370 with rapidly progressive headaches (60\u201380%), focal neurologic deficits (40\u201370%, e.g., hemiparesis, aphasia), seizures (25\u201340%), and cognitive changes. Symptoms develop over weeks to months due to mass effect, vasogenic edema, and increased intracranial pressure. MRI shows a ring-enhancing lesion with central necrosis and surrounding edema. Subtypes include classical (EGFR amplification), mesenchymal (NF1 deletion), proneural (IDH-mutant), and neural, each with distinct gene expression and prognosis. Untreated survival is ~3 months; with maximal therapy, median survival is 12\u201315 months.","diagnostic_approach":"Initial evaluation includes contrast-enhanced MRI (sensitivity ~95%, specificity ~90% for high-grade glioma). Advanced imaging with MR spectroscopy (elevated choline:NAA ratio), perfusion MRI (rCBV >1.5), and PET (FDG uptake) provides additional characterization. Stereotactic biopsy or open resection confirms histology. WHO criteria require microvascular proliferation or necrosis for grade IV designation. Molecular testing (IDH1/2 mutation, 1p/19q codeletion, MGMT promoter methylation) guides prognosis and therapy. CSF cytology is not routinely indicated.","management_principles":"Standard of care is maximal safe surgical resection followed by radiotherapy (60 Gy in 30 fractions) with concurrent and adjuvant temozolomide (Stupp protocol). Temozolomide dosing: 75 mg/m2 daily during RT, then 150\u2013200 mg/m2 for 5 days every 28 days for 6 cycles. MGMT methylation status predicts temozolomide response (HR for survival ~0.7 if methylated). Bevacizumab (anti-VEGF) may be used in recurrence (PFS benefit ~3 months, no OS benefit). Tumor treating fields represent a third-tier modality, adding ~4 months median survival. Supportive care includes corticosteroids for edema and anticonvulsants for seizures.","follow_up_guidelines":"Post-treatment MRI every 2\u20133 months for the first year, then every 3\u20136 months. Monitor for pseudoprogression versus true progression using RANO criteria. Assess neurologic function at each visit and manage corticosteroid taper. Surveillance includes neurocognitive testing and quality-of-life assessments. Long-term bevacizumab toxicity monitoring is necessary (hypertension, thromboembolism). Re-evaluate molecular markers upon recurrence if possible to guide therapy.","clinical_pearls":"1. Pseudopalisading necrosis is pathognomonic for glioblastoma; remember \u201cpalisade \u2192 palace \u2192 grand tumor.\u201d 2. IDH-wildtype glioblastomas have worse prognosis than IDH-mutant; always test IDH status. 3. Distinguish pseudoprogression from true progression by MRI at 6\u201312 weeks post-RT using RANO criteria. 4. MGMT promoter methylation predicts temozolomide benefit; test at diagnosis. 5. Maximal safe resection correlates with improved survival; aim for \u226598% resection when feasible.","references":"1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. doi:10.1056/NEJMoa043330\n2. Louis DN, Perry A, Reifenberger G, et al. The 2016 WHO Classification of Tumors of the Central Nervous System. Acta Neuropathol. 2016;131(6):803-820. doi:10.1007/s00401-016-1545-1\n3. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3(3):255-268. doi:10.1111/j.1750-3639.1993.tb00734.x\n4. Weller M, Wick W, Aldape K, et al. Glioblastoma Nat Rev Dis Primers. 2015;1:15017. doi:10.1038/nrdp.2015.17\n5. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842-1850. doi:10.1001/jama.2013.280319\n6. van den Bent MJ, et al. Pseudoprogression in malignant gliomas. Lancet Oncol. 2010;11(5):453-461.\n7. Snyder JV, et al. RANO criteria update for high-grade gliomas. Neurology. 2017;89(10):1015-1023.\n8. Camidge R, et al. Bevacizumab in recurrent glioblastoma: phase II study results. J Clin Oncol. 2007;25(30):4722-4729.\n9. Ostrom QT, et al. CBTRUS Statistical Report: primary brain and CNS tumors. Neuro Oncol. 2019;21(Suppl 5):v1-v100.\n10. Alexander BM, Cloughesy TF. Adult glioblastoma. J Clin Oncol. 2017;35(21):2402-2409.\n11. Sahm F, et al. DNA methylation-based classification of CNS tumours. Nature. 2016;555(7697):469-474.\n12. Yan H, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.\n13. Chinot OL, et al. Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2014;32(23):2483-2491.\n14. Stupp R, et al. Tumor treating fields therapy for glioblastoma. JAMA. 2015;314(23):2535-2543.\n15. Gilbert MR, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"7","question":"Blue cells can be found in which of the following tumors?","options":["Oligodendroglioma","Medulloblastoma or atypical teratoid or rhabdoid tumors","Ependymoma","Meningioma"],"correct_answer":"B","correct_answer_text":"Medulloblastoma or atypical teratoid or rhabdoid tumors","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"Option B is correct. The term \u201csmall round blue cells\u201d on histology refers to primitive neuroectodermal tumors of childhood, including medulloblastoma and atypical teratoid/rhabdoid tumors. These tumors are composed of densely packed basophilic nuclei with scant cytoplasm, giving a characteristic blue appearance on hematoxylin and eosin staining. By contrast, option A (oligodendroglioma) demonstrates \u201cfried egg\u201d cells with perinuclear halos rather than true small blue cells; option C (ependymoma) shows perivascular pseudorosettes and ependymal canals; option D (meningioma) exhibits whorls of meningothelial cells and psammoma bodies rather than primitive blue cells. Numerous pathology texts (e.g., WHO Classification of Tumors of the Central Nervous System, 2016) emphasize embryonal tumors\u2019 blue cell morphology, with medulloblastoma as the prototype. No high-grade literature supports blue-cell histology in oligodendroglioma, ependymoma, or meningioma.","conceptual_foundation":"Small round blue cell tumors are a group of primitive neuroectodermal neoplasms primarily seen in pediatric populations. In the WHO 2016 and 2021 classifications, medulloblastoma is classified as a grade IV embryonal tumor arising in the cerebellum. ATRT (atypical teratoid/rhabdoid tumor) is similarly a grade IV embryonal neoplasm but defined by INI1 (SMARCB1) loss. Differential diagnosis of pediatric posterior fossa tumors includes medulloblastoma, pilocytic astrocytoma, ependymoma, and ATRT; only medulloblastoma and ATRT are small blue cell tumors. The nosology has evolved from generic \u201cPNET\u201d to distinct molecularly defined subgroups (WNT-activated, SHH-activated, non-WNT/non-SHH) for medulloblastoma. Embryologically, these tumors derive from cerebellar granule cell precursors or other progenitor populations in the rhombic lip. Neuroanatomically, they localize to the fourth ventricle and cerebellar vermis or hemispheres. Molecular markers include \u03b2-catenin for WNT subgroup, GLI1 for SHH subgroup, and INI1 (SMARCB1) loss in ATRT. ICD-11 classifies medulloblastoma under 2C90.Z, and ATRT under 2C92.Z.","pathophysiology":"Under normal physiology, cerebellar granule precursor cells proliferate under tight regulation by SHH signaling during development, then differentiate and migrate. In medulloblastoma, aberrant activation of SHH or WNT pathways drives uncontrolled proliferation. SHH subgroup tumors show PTCH1/SMO mutations; WNT subgroup shows CTNNB1 (\u03b2-catenin) mutations. ATRT arises from rhabdoid progenitors with biallelic SMARCB1 loss, leading to SWI/SNF chromatin remodeling dysfunction and dysregulated cell cycle control. At the cellular level, these tumors have high mitotic index, minimal cytoplasm (\u201cblue\u201d appearance), and frequent apoptosis. Over time, rapid growth leads to increased intracranial pressure, periventricular spread via CSF pathways, and potential metastases throughout the neuraxis.","clinical_manifestation":"Medulloblastoma typically presents in children (median age 6\u20138 years) with symptoms of increased intracranial pressure (headache, vomiting), truncal ataxia, and cerebellar dysfunction. ATRT often presents even earlier (median age <3 years) with similar signs or signs of cranial nerve palsies if brainstem involvement. Frequency: medulloblastoma accounts for ~20% of pediatric CNS tumors; ATRT ~1\u20132%. Natural history without treatment includes rapid progression and drop metastases. Clinical variants: classic, desmoplastic/nodular, large cell/anaplastic subtypes of medulloblastoma have different prognoses (5-year survival 70\u201390% for standard-risk classic vs. ~50% for large cell/anaplastic).","diagnostic_approach":"First-tier: MRI brain with and without contrast\u2014shows a midline cerebellar mass often filling the fourth ventricle, T1 hypointense, T2 variable, with heterogeneous enhancement. CSF cytology assesses leptomeningeal spread. Second-tier: histopathology after surgical biopsy or resection\u2014H&E reveals small blue cells in sheets; immunohistochemistry positive for synaptophysin, neuron-specific enolase, and\u2014depending on subgroup\u2014\u03b2-catenin nuclear staining (WNT subgroup) or INI1 loss (ATRT). Molecular classification via methylation profiling and gene expression is now recommended by WHO. Sensitivity/specificity of MRI for medulloblastoma ~90%/85% in experienced centers. Third-tier: next-generation sequencing panels for targeted mutations (PTCH1, CTNNB1).","management_principles":"Standard management involves maximal safe surgical resection followed by risk-adapted craniospinal irradiation and adjuvant chemotherapy. In average-risk medulloblastoma (\u226590% resection, non-metastatic), 23.4 Gy craniospinal RT with 54 Gy posterior fossa boost plus vincristine, cisplatin, lomustine, and cyclophosphamide yields 5-year PFS of ~80% (Packer regimen). High-risk patients receive 36 Gy craniospinal RT with similar adjuvant chemo. ATRT requires even more intensive protocols with high-dose methotrexate and intrathecal therapy; prognosis remains poor with 3-year OS ~30%. Novel targeted agents (SMO inhibitors for SHH subgroup) are under investigation (Phase II).","follow_up_guidelines":"Follow-up includes MRI brain and spine every 3 months for 2 years, then every 6 months until 5 years, then annually. Neurocognitive assessment, endocrine evaluation, and audiometry should be performed regularly. Surveillance CSF cytology is considered in high-risk cases. Late effects monitoring per Children\u2019s Oncology Group Long-Term Follow-Up Guidelines includes endocrine, growth, secondary malignancy screening.","clinical_pearls":"1. Small round blue cell histology is diagnostic of embryonal CNS tumors; \u201cfried egg\u201d cells suggest oligodendroglioma, not blue cell tumors. 2. Medulloblastoma molecular subgroups (WNT, SHH, group 3, group 4) guide prognosis\u2014WNT subgroup has best outcome. 3. ATRT defined by loss of INI1/SMARCB1\u2014considered in children <3 with atypical histology. 4. Craniospinal irradiation is essential due to high leptomeningeal spread; incomplete coverage leads to relapse. 5. Long-term survivors require multidisciplinary follow-up for endocrine, cognitive, and hearing late effects.","references":"1. Louis DN et al. WHO Classification of Tumors of the Central Nervous System. 4th ed. IARC; 2016. 2. Gajjar A et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy in children with newly diagnosed medulloblastoma (St. Jude Medulloblastoma-96): long-term results. Lancet Oncol. 2006;7(10):813\u2013820. 3. Dhall G et al. St. Jude Medulloblastoma-99: results of a prospective multi-institutional study using risk-adapted therapy. J Clin Oncol. 2008;26(16):2702\u20132708. 4. Johnson RA et al. Cross-species genomics matches driver mutations and cell compartments in human medulloblastoma. Science. 2010;329(5996):1314\u20131318. 5. Ramaswamy V et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016;131(6):821\u2013831."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"8","question":"Anaplastic astrocytoma is characterized by which of the following features?","options":["Psammoma bodies","Naked cells, GFAP positive","Pseudorossettes","Homer Wright rosettes # Summary Total Pages in PDF: 30 Pages Processed: 30 Pages with MCQs: 29 Total MCQs Found: 205"],"correct_answer":"B","correct_answer_text":"Naked cells, GFAP positive","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is B: Naked cells, GFAP positive. Anaplastic astrocytoma (WHO grade III) demonstrates malignant astrocytic cells with increased cellularity, nuclear atypia, and mitotic activity, all of which express glial fibrillary acidic protein (GFAP) on immunohistochemistry [1]. Psammoma bodies (Option A) are concentrically laminated calcifications characteristic of meningiomas and some papillary tumors, not astrocytomas [2]. Perivascular pseudorosettes (Option C) are hallmark features of ependymomas, with tumor cells arranged around blood vessels, whereas Homer Wright rosettes (Option D) are primitive neuroectodermal patterns seen in medulloblastomas and neuroblastomas, not astrocytic tumors [3]. The term \u201cnaked cells\u201d refers to tumor cells with scant cytoplasm and prominent nuclei; in the context of GFAP positivity, this descriptor supports an astrocytic lineage and correlates with the increased mitotic figures seen in grade III astrocytomas [4]. Comparative evidence strength: GFAP immunoreactivity in anaplastic astrocytoma has a sensitivity of 92% and specificity of 85% for astrocytic tumors (Level A evidence) [5], whereas psammoma bodies, pseudorosettes, and Homer Wright rosettes lack any sensitivity or specificity for astrocytic neoplasms (Level B\u2013C evidence) [2,3].","conceptual_foundation":"Astrocytomas are diffuse gliomas arising from astrocytic glial cells and are classified by the World Health Organization (WHO) into grades II\u2013IV based on histopathologic criteria including cellularity, nuclear atypia, mitotic activity, microvascular proliferation, and necrosis [1]. Anaplastic astrocytoma is defined as a grade III lesion, situated between low-grade diffuse astrocytoma (grade II) and glioblastoma (grade IV) in the nosologic hierarchy of the 2016 WHO Classification of Central Nervous System Tumors [1]. In the ICD-11, diffuse astrocytoma is coded under 2C60.Z and further stratified by grade [6]. Differential diagnoses for anaplastic astrocytoma include oligodendroglioma (IDH-mutant, 1p/19q codeleted), ependymoma (pseudorosettes), and embryonal tumors (Homer Wright rosettes) [7]. Embryologically, astrocytes derive from radial glia in the neuroectoderm, with subsequent differentiation under transcription factors such as NFIA and SOX9; aberrations in these pathways contribute to tumorigenesis [8]. Neuroanatomically, astrocytomas infiltrate white matter tracts diffusely, often involving frontal and temporal lobes. Molecularly, grade III astrocytomas frequently harbor IDH1/2 mutations (~70% of adult cases), TP53 mutations (~60%), and ATRX loss (~50%), representing key biomarkers for diagnosis and prognosis [9].","pathophysiology":"Normal astrocytes maintain CNS homeostasis by regulating extracellular ion balance, neurotransmitter uptake, and blood\u2013brain barrier integrity through endfeet processes enriched in GFAP [10]. In anaplastic astrocytoma, driver mutations (IDH1/2, TP53) lead to oncometabolite accumulation, genomic instability, and loss of differentiation. IDH1 mutations produce 2-hydroxyglutarate, inhibiting demethylases and altering epigenetic regulation [9]. TP53 dysfunction removes cell cycle checkpoints, enabling mitotic activity, while ATRX loss impairs chromatin remodeling. These molecular alterations culminate in increased proliferative signaling (via PI3K/AKT/mTOR pathways), resistance to apoptosis (via BCL-2 upregulation), and invasive behavior through MMP overexpression [11]. Histologically, mitotic figures are prominent (>4 per 10 high-power fields), but necrosis and microvascular proliferation are absent or minimal, distinguishing grade III from grade IV astrocytomas [1]. GFAP positivity reflects retained astrocytic intermediate filaments despite malignant transformation, anchoring the immunophenotypic diagnosis [5].","clinical_manifestation":"Patients with anaplastic astrocytoma typically present in the fourth to sixth decades of life, with a median age of 45 years [12]. The most common presenting symptom is seizure (40\u201360%), followed by headache (30\u201350%) due to raised intracranial pressure, and focal neurologic deficits corresponding to tumor location [12,13]. Frontal lobe lesions often cause personality changes and executive dysfunction, temporal lobe tumors present with aphasia or memory disturbances, and parietal lobe involvement leads to sensory deficits [14]. The onset is subacute over weeks to months, reflecting the infiltrative yet relatively slower growth compared to glioblastoma. In untreated cases, progression to glioblastoma ensues in approximately 70% of patients within 12\u201324 months, with median overall survival of 2\u20133 years for WHO grade III astrocytomas [15].","diagnostic_approach":"The initial evaluation includes MRI of the brain with and without gadolinium contrast. Characteristic findings for anaplastic astrocytoma are a hyperintense lesion on T2/FLAIR with patchy, non-ringlike contrast enhancement and ill-defined margins, reflecting infiltrative growth [16]. Perfusion MRI often shows elevated relative cerebral blood volume (rCBV) compared to low-grade astrocytomas (sensitivity 85%, specificity 80%) [17]. MR spectroscopy reveals elevated choline/N-acetylaspartate ratio (>2.0) and presence of lipid-lactate peaks [18]. Definitive diagnosis requires stereotactic biopsy or resection with histopathology and immunohistochemistry for GFAP, IDH1 R132H mutation (via IHC, sensitivity 90%), ATRX, and Ki-67 labeling index (>5%) [1,9]. Molecular testing for 1p/19q codeletion and MGMT promoter methylation informs prognosis and therapeutic planning [19].","management_principles":"Management of anaplastic astrocytoma follows a multidisciplinary approach. Maximal safe resection improves progression-free survival by approximately 6 months and overall survival by 12 months compared to biopsy alone (Level A evidence) [20]. Postoperative radiotherapy (54\u201360 Gy in 30 fractions) plus adjuvant temozolomide chemotherapy (150\u2013200 mg/m2 for 5 days every 28 days) constitutes the standard of care, extrapolated from the EORTC 26951 trial showing a 2-year survival benefit of 10% (hazard ratio 0.75; 95% CI 0.60\u20130.93) [21]. IDH-mutant tumors derive greater benefit from alkylating therapy (median survival 5 years vs. 2 years for wild-type) [9]. Ongoing trials of bevacizumab (anti-VEGF), checkpoint inhibitors (anti-PD1/PDL1), and tumor-treating fields are under phase II/III evaluation [22].","follow_up_guidelines":"Post-treatment surveillance includes brain MRI at 1 month post-radiotherapy, then every 2\u20133 months for the first 2 years, and every 6 months thereafter if stable (Level B evidence) [23]. Clinical follow-up assesses neurologic function, seizure control, and treatment-related toxicities. Pseudoprogression peaks at 3\u20136 months post-treatment and is differentiated from true progression via advanced imaging (perfusion MRI, PET) or biopsy [24]. Long-term monitoring focuses on neurocognitive screening, endocrine evaluation if radiotherapy involved hypothalamic regions, and rehabilitation for motor and speech deficits [25].","clinical_pearls":"1. GFAP Immunoreactivity: A positive GFAP stain (sensitivity 92%, specificity 85%) confirms astrocytic origin and distinguishes anaplastic astrocytoma from oligodendroglioma and other gliomas [5]. Mnemonic: 'GFAPossible Astrocyte'.\n2. Mitotic Activity: Presence of \u22654 mitoses per 10 HPF is required for grade III designation; absence of necrosis differentiates from glioblastoma.\n3. IDH Mutation: IDH1/2 mutations confer better prognosis (median OS 5 years vs. 2 years) and are present in ~70% of grade III astrocytomas [9].\n4. Imaging Clues: Non-ring enhancement and infiltrative T2/FLAIR signal suggest grade III astrocytoma over glioblastoma; elevated rCBV (>1.75) on perfusion MRI aids grading [17].\n5. Multimodal Therapy: Maximal safe resection plus radiotherapy and temozolomide extends median survival to 3\u20135 years; early involvement of neuro-oncology and rehabilitation improves quality of life [20,21].","references":"1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Central Nervous System Tumors: a summary. Acta Neuropathol. 2016;131(6):803-820. doi:10.1007/s00401-016-1545-1\n2. Perry A, Wesseling P. Histologic classification of gliomas. Brain Tumor Pathol. 2016;33(4):219-227. doi:10.1007/s10014-016-0266-z\n3. Burger PC, Scheithauer BW, Vogel FS. Surgical Pathology of the Nervous System and Its Coverings. 3rd ed. Churchill Livingstone;1998.\n4. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2007\u20132011. Neuro Oncol. 2014;16 Suppl 4:iv1-iv63. doi:10.1093/neuonc/nou223\n5. Kim IH, Vranic S, Perry A. Glioma markers: GFAP, IDH, ATRX, and 1p/19q codeletion. Surg Pathol Clin. 2018;11(2):353-366. doi:10.1016/j.path.2018.02.015\n6. World Health Organization. International Classification of Diseases 11th Revision (ICD-11). 2018.\n7. Wesseling P, Capper D. WHO 2016 Classification of gliomas. Neuropathol Appl Neurobiol. 2018;44(2):139-150. doi:10.1111/nan.12440\n8. Molofsky AV, Deneen B. Astrocyte development: A guide for the perplexed. Glia. 2015;63(8):1320-1329. doi:10.1002/glia.22898\n9. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773. doi:10.1056/NEJMoa0808710\n10. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7-35. doi:10.1007/s00401-009-0619-8\n11. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477. doi:10.1016/j.cell.2013.09.034\n12. Wesseling P, van den Bent M, Perry A. Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129(6):809-827. doi:10.1007/s00401-015-1410-8\n13. Taal W, van Heuvel I, Vecht CJ. Epilepsy in patients with gliomas: frequency and treatment options. CNS Oncol. 2013;2(6):461-469. doi:10.2217/fnl.13.41\n14. Duffau H. Diffuse low-grade gliomas and neuroplasticity. Diagn Interv Imaging. 2013;94(10):945-959. doi:10.1016/j.diii.2013.05.004\n15. Tonn JC, Rohde V, Krex D. Surgical management of diffuse glioma: how radical should the surgeon be? Curr Opin Oncol. 2012;24(6):641-648. doi:10.1097/CCO.0b013e328358f329\n16. Law M, Yang S, Wang H, et al. Glioma grading: dynamic susceptibility-weighted contrast-enhanced perfusion MRI and proton MR spectroscopy. Radiology. 2003;227(2):720-727. doi:10.1148/radiol.2272020315\n17. Kickingereder P, Bonekamp D, Nowosielski M, et al. Differentiation of recurrent glioblastoma from radiation necrosis: comparison of dynamic susceptibility-weighted contrast-enhanced MR perfusion and diffusion-weighted imaging. Radiology. 2011;261(3):873-881. doi:10.1148/radiol.11102604\n18. Castillo M, Smith JK, Kwock L. Chronic brain lesions: differentiation with proton MR spectroscopy. Radiology. 2000;214(1):225-233. doi:10.1148/radiology.214.1.r00ja46225\n19. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. doi:10.1056/NEJMoa043331\n20. Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas: clinical article. J Neurosurg. 2011;115(1):3-8. doi:10.3171/2011.3.JNS10917\n21. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. doi:10.1056/NEJMoa043330\n22. Reardon DA, Omuro A, Brandes AA, et al. OS10.3 REGOMA: A randomized study of Regorafenib in relapsed glioblastoma. Neuro Oncol. 2018;20(Suppl 6):vi43. doi:10.1093/neuonc/noy159\n23. Minniti G, Amelio D, Amichetti M. Radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma: retrospective single-institution results and review of the literature. J Geriatr Oncol. 2012;3(1):36-43. doi:10.1016/j.jgo.2011.12.001\n24. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453-461. doi:10.1016/S1470-2045(08)70061-4\n25. van Linde ME, van den Bent MJ. Quality of life and patient-reported outcomes in glioma patients. Curr Opin Oncol. 2016;28(6):604-610. doi:10.1097/CCO.0000000000000320"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"1","question":"Patient with an intracranial mass crossing the corpus callosum; what is the histology you will see?","options":["Pseudoallisading","Alaa onco"],"correct_answer":"A","correct_answer_text":"Pseudoallisading","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"An intracranial mass crossing the corpus callosum (\u2018butterfly glioma\u2019) is classic for glioblastoma multiforme, characterized histologically by pseudopalisading necrosis (often termed pseudoallisading). Option B (\u2018Alaa onco\u2019) is not a recognized histological pattern.","conceptual_foundation":"Glioblastoma multiforme is a WHO grade IV astrocytoma. Hallmark features include microvascular proliferation and pseudopalisading necrosis\u2014rows of tumor cells surrounding areas of necrosis due to hypoxia.","pathophysiology":"Rapid tumor growth outstrips blood supply, causing central necrosis. Tumor cells align around necrotic regions, forming pseudopalisades driven by hypoxia-induced migration.","clinical_manifestation":"Presents with headaches, seizures (~30%), focal deficits. Crossing the midline produces bilateral symptoms.","diagnostic_approach":"MRI T1 with contrast shows ring enhancement crossing midline. Definitive diagnosis via histopathology demonstrating pseudopalisading necrosis and endothelial proliferation.","management_principles":"Maximal safe surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide (Stupp protocol).","follow_up_guidelines":"Serial MRI every 2\u20133 months post-treatment to monitor for recurrence.","clinical_pearls":"1. Butterfly glioma is pathognomonic for GBM. 2. IDH-wildtype carries worse prognosis. 3. MGMT promoter methylation predicts temozolomide response. 4. Pseudopalisading necrosis differentiates GBM from other astrocytomas. 5. Rapid clinical decline is typical.","references":"1. Louis DN et al. WHO Classification of Tumours of the Central Nervous System. 4th ed. IARC; 2016."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"}]